Caliper's Q2 Revenues Fall, but Shares Rise as It Beats Expectations | GenomeWeb

NEW YORK (GenomeWeb News) – Caliper Life Sciences today reported that its second-quarter revenues fell around 6 percent, but were up 8 percent on an organic basis, as the firm trimmed its net loss. It also beat analysts' consensus estimate for both revenues and net loss.

The Hopkinton, Mass.-based firm's stock was up 11 percent to $1.95 in early Thursday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.